Ozarks Tech gets permission to expand nursing program from 24 to 150 seats
Ozarks Technical Community College has secured permission to expand its nursing program to help meet the need in southwest Missouri.
This month, the Missouri Board of Nursing signed off on Ozarks Tech increasing the number of available seats in its Associate of Science in Nursing−Direct Entry program from 24 to 150. A site visit to confirm the expansion is set for summer.
Ozarks Tech increased its capacity as part of the Alliance for Healthcare Education, a collaborative effort between Ozarks Tech, CoxHealth, Missouri State University and Springfield Public Schools.
'We have been working intently toward the growth of this high-demand program, which will be greatly beneficial for future nursing students in our region,' said Ozarks Tech Chancellor Hal Higdon, in a news release.
He added: "This expansion will pay dividends to the people of southwest Missouri as they seek medical care in the future.'
The expansion of the ASN-D program will introduce five cohorts of 30 students each, allowing 150 students to enroll each year.
This model, unique to the region, enables new students to begin every eight weeks, offering greater flexibility and reducing wait times for program entry.
Two of the cohorts will be an evening and weekend hybrid option, two will be traditional seated courses during the day and one will be a daytime hybrid option. The hybrid option is a mix of in-person and online learning.
More: Ozarks Tech plans tuition increase next year. Here's why, how much
Students interested in the program can use a range of financial aid options including the A+ Scholarship Program and the Fast Track Workforce Incentive Grant.
'This expansion is a game-changer for our community,' said Aaron Light, dean of health sciences at OTC. 'Bottom line is we are offering multitudes of ways to get into nursing, and this expansion makes Ozarks Tech a great choice when you are looking for options to train in this field.'
Applications are now open for new students, with the first cohort of students set to begin classes in October.
For more information or to apply, go to otc.edu or contact Michelle Crum at crumm@otc.edu or Aaron Light at lighta@otc.edu.
This article originally appeared on Springfield News-Leader: Ozarks Tech secures permission to expand nursing program
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
a day ago
- The Hill
Lawmakers, USDA seek to combat New World screwworm along the southern border
Just a few hundred miles from our southern border, a flesh-eating parasite has been detected in Mexico, putting America's farmers and ranchers on watch. The New World screwworm is a parasitic fly that lays its eggs in the open wounds of livestock, primarily cattle and sheep, deer and other wildlife, and on rare occasions, humans and pets. Once hatched, the fly's larvae feed on tissue, leading to severe infection and often death. If this parasite were ever to reach the United States, our agricultural economy and supply chain would be in serious trouble. That is not a hypothetical scenario. Flare-ups have occurred within our borders in the past, costing American producers hundreds of millions of dollars. Mrs. D., a Central Texas rancher, remembers all too well the devastation of the last major screwworm outbreak in the United States that took place during the 1960s. 'Every day from dawn to dusk, my husband would ride horseback to find animals affected by the screwworm. We worked tirelessly to ensure our livestock survived. We had to make sure our calves were born in the winter to stand a chance against the fly that caused the screwworm because the flies are not as prevalent in the cold weather.' Although screwworms were eradicated from the U.S. in the 1960s using a sterilized fly technique, all the signs are there for a repeat scenario. As of March of this year, 369 confirmed cases had been reported in Mexico, creeping north from its confinement zone in Central America and towards the United States. As the representative of the largest congressional district in Texas, I have heard repeatedly from my constituents that a reemergence of New World screwworm is their biggest concern. Texas tops the charts for beef production in the nation, and some of my district's counties have more sheep and goats than live human beings. There is no doubt that a screwworm outbreak would be absolutely devastating to communities like mine. I am not alone in these concerns. In March, 43 of my colleagues joined me in bipartisan outreach to the Agriculture Department to offer congressional support on screwworm eradication efforts. I also introduced the STOP Screwworms Act along with 31 of my House colleagues and Sens. John Cornyn (R-Texas), Ted Cruz (R-Texas), Cindy Hyde-Smith (R-Miss.), Ben Ray Lujan (D-N.M.), and Martin Heinrich (D-N.M). This important legislation would establish a sterile fly production facility in the U.S. — a critical step in our fight to shore up our domestic infrastructure against this deadly parasite. Fortunately, Agriculture Secretary Brooke Rollins has been incredibly proactive on this issue. This week, I joined Rollins to announce the launch of an $8.5 million sterile New World screwworm fly dispersal facility in South Texas and a five-pronged plan to enhance the Agriculture Department's ability to detect, control and eliminate this pest. Per the Agriculture Department, the facility in South Texas is expected to be ready within six months. President Trump and Rollins have made protecting America's agriculture industry a priority. Together, we will fight to codify executive branch wins into long-term legislative solutions. Tony Gonzales represents Texas's 23rd District in the U.S. House of Representatives. He serves as the chairman of the Congressional Hispanic Conference and represents the largest congressional district in Texas, spanning over 800 miles of the southern border.
Yahoo
3 days ago
- Yahoo
ReGelTec Announces First Patient Treated in U.S. IDE Clinical Trial for HYDRAFIL System to Treat Chronic Low Back Pain
BALTIMORE, June 18, 2025--(BUSINESS WIRE)--ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced it has treated the first patient in its HYDRAFIL-D FDA investigational device exemption (IDE) clinical trial for its HYDRAFIL® System for disc augmentation. The patient was enrolled by Kas Amirdelfan, M.D., an interventional pain physician and founding member of Boomerang Healthcare, Inc. in Walnut Creek, Calif. The HYDRAFIL System is an outpatient procedure offering interventional pain physicians and patients a new treatment designed to reduce pain and improve daily function without the need for an invasive surgery. The launch of the HYDRAFIL-D U.S. study follows the company's receipt of CE Mark for the HYDRAFIL System based on promising results of clinical studies performed outside the United States on 75 patients. The studies showed that patients treated with HYDRAFIL experienced clinically and statistically significant improvements in pain and disability, with more than 80% improvement in Oswestry Disability Index (ODI) scores and greater than 70% reduction in Numeric Pain Rating Scale scores, with reductions sustained for two years in the 63 patients that have completed their two-year follow-up visit. "An overwhelming majority of my chronic low back pain patients either do not want or are not good candidates for invasive spine surgeries, yet they continue to feel debilitated, without many treatment options," said Dr. Amirdelfan. "The early data on HYDRAFIL is compelling and promising for our subjects. I am excited to be working with ReGelTec and the other principal investigators to enroll the HYDRAFIL-D Study and evaluate the impact of HYDRAFIL on patients with degenerative disc disease." The HYDRAFIL-D study is a 225-patient, multicenter, single-blinded, randomized, controlled trial evaluating the safety and effectiveness of the HYDRAFIL System to support FDA approval. The study will measure improvements in pain and disability, reliance on opioid medications, and the need for invasive medical procedures in patients with chronic low back pain due to degenerative disc disease. The protocol includes an interim safety analysis when the first sixty patients complete their six-month follow-up visit. There are nine study sites currently enrolling patients in Birmingham, Ala.; Walnut Creek, Calif.; Greenwood Village, Colo.; Jasper, Ga.; Shreveport, La.; Edmond, Okla.; Tyler, Texas; Richmond, Virginia; and Calgary, Canada, with additional sites being added. More than one in 10 U.S. adults suffer from chronic low back pain.1 About 42% of this population, or more than 10 million Americans, has degenerative disc disease2, a condition that is the largest contributor to chronic low back pain where intervertebral discs in the spine deteriorate and lose their height and volume. Degenerating discs cause vertebrae to move abnormally and inflame surrounding spinal structures, muscles, joints and nerves, resulting in pain in the back and sometimes the leg. Performed in an outpatient procedure under local anesthesia, ReGelTec's HYDRAFIL System delivers a permanent hydrogel into a degenerated disc via a needle to fill cracks and fissures and recruit water into the disc to restore natural biomechanics and provide pain relief. When the hydrogel implant solidifies in the disc, it distributes the load and strain felt in that intervertebral segment to improve function and reduce the pain signaling to the brain. "I have been working with doctors and scientists for more than twenty years to develop a treatment for chronic low back pain, and in HYDRAFIL, we believe we've built a low-risk, effective option to fill a major market need," said Tony Lowman, the inventor of HYDRAFIL and founder of ReGelTec. "We look forward to fully enrolling the trial and securing FDA approval for the HYDRAFIL System so that patients in the United States with degenerative disc disease can benefit from this innovative, minimally invasive treatment option." Patients interested in learning more about the HYDRAFIL-D Study can visit ABOUT REGELTEC, INC. ReGelTec is a clinical-stage privately held biomedical company dedicated to developing and commercializing a percutaneous hydrogel implant for the treatment of chronic low back pain due to degenerative disc disease. ReGelTec's HYDRAFIL System is an outpatient disc augmentation procedure where a permanent hydrogel is delivered into a degenerated disc via a needle to fill cracks and fissures and recruit water into the disc to restore natural biomechanics and provide pain relief. For more information, please visit 1 Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-1694. doi: 10.1002/acr.22890. PMID: 26991822; PMCID: PMC5027174. 2 Michael J. DePalma, Jessica M. Ketchum, Thomas Saullo, What Is the Source of Chronic Low Back Pain and Does Age Play a Role?, Pain Medicine, Volume 12, Issue 2, February 2011, Pages 224–233, View source version on Contacts MEDIA CONTACT: Sam ChoinskiPazanga Health Communications(860) 301-5058schoinski@ Sign in to access your portfolio
Business Wire
3 days ago
- Business Wire
ReGelTec Announces First Patient Treated in U.S. IDE Clinical Trial for HYDRAFIL System to Treat Chronic Low Back Pain
BALTIMORE--(BUSINESS WIRE)-- ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced it has treated the first patient in its HYDRAFIL-D FDA investigational device exemption (IDE) clinical trial for its HYDRAFIL ® System for disc augmentation. The patient was enrolled by Kas Amirdelfan, M.D., an interventional pain physician and founding member of Boomerang Healthcare, Inc. in Walnut Creek, Calif. The HYDRAFIL System is an outpatient procedure offering interventional pain physicians and patients a new treatment designed to reduce pain and improve daily function without the need for an invasive surgery. The launch of the HYDRAFIL-D U.S. study follows the company's receipt of CE Mark for the HYDRAFIL System based on promising results of clinical studies performed outside the United States on 75 patients. The launch of the HYDRAFIL-D U.S. study follows the company's receipt of CE Mark for the HYDRAFIL System based on promising results of clinical studies performed outside the United States on 75 patients. The studies showed that patients treated with HYDRAFIL experienced clinically and statistically significant improvements in pain and disability, with more than 80% improvement in Oswestry Disability Index (ODI) scores and greater than 70% reduction in Numeric Pain Rating Scale scores, with reductions sustained for two years in the 63 patients that have completed their two-year follow-up visit. 'An overwhelming majority of my chronic low back pain patients either do not want or are not good candidates for invasive spine surgeries, yet they continue to feel debilitated, without many treatment options,' said Dr. Amirdelfan. 'The early data on HYDRAFIL is compelling and promising for our subjects. I am excited to be working with ReGelTec and the other principal investigators to enroll the HYDRAFIL-D Study and evaluate the impact of HYDRAFIL on patients with degenerative disc disease.' The HYDRAFIL-D study is a 225-patient, multicenter, single-blinded, randomized, controlled trial evaluating the safety and effectiveness of the HYDRAFIL System to support FDA approval. The study will measure improvements in pain and disability, reliance on opioid medications, and the need for invasive medical procedures in patients with chronic low back pain due to degenerative disc disease. The protocol includes an interim safety analysis when the first sixty patients complete their six-month follow-up visit. There are nine study sites currently enrolling patients in Birmingham, Ala.; Walnut Creek, Calif.; Greenwood Village, Colo.; Jasper, Ga.; Shreveport, La.; Edmond, Okla.; Tyler, Texas; Richmond, Virginia; and Calgary, Canada, with additional sites being added. More than one in 10 U.S. adults suffer from chronic low back pain. 1 About 42% of this population, or more than 10 million Americans, has degenerative disc disease 2, a condition that is the largest contributor to chronic low back pain where intervertebral discs in the spine deteriorate and lose their height and volume. Degenerating discs cause vertebrae to move abnormally and inflame surrounding spinal structures, muscles, joints and nerves, resulting in pain in the back and sometimes the leg. Performed in an outpatient procedure under local anesthesia, ReGelTec's HYDRAFIL System delivers a permanent hydrogel into a degenerated disc via a needle to fill cracks and fissures and recruit water into the disc to restore natural biomechanics and provide pain relief. When the hydrogel implant solidifies in the disc, it distributes the load and strain felt in that intervertebral segment to improve function and reduce the pain signaling to the brain. 'I have been working with doctors and scientists for more than twenty years to develop a treatment for chronic low back pain, and in HYDRAFIL, we believe we've built a low-risk, effective option to fill a major market need,' said Tony Lowman, the inventor of HYDRAFIL and founder of ReGelTec. 'We look forward to fully enrolling the trial and securing FDA approval for the HYDRAFIL System so that patients in the United States with degenerative disc disease can benefit from this innovative, minimally invasive treatment option.' Patients interested in learning more about the HYDRAFIL-D Study can visit ABOUT REGELTEC, INC. ReGelTec is a clinical-stage privately held biomedical company dedicated to developing and commercializing a percutaneous hydrogel implant for the treatment of chronic low back pain due to degenerative disc disease. ReGelTec's HYDRAFIL System is an outpatient disc augmentation procedure where a permanent hydrogel is delivered into a degenerated disc via a needle to fill cracks and fissures and recruit water into the disc to restore natural biomechanics and provide pain relief. For more information, please visit 1 Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-1694. doi: 10.1002/acr.22890. PMID: 26991822; PMCID: PMC5027174. 2 Michael J. DePalma, Jessica M. Ketchum, Thomas Saullo, What Is the Source of Chronic Low Back Pain and Does Age Play a Role?, Pain Medicine
